NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its fourth quarter revenues rose 10 percent year over year, buoyed by an increase in its prostate cancer testing business and international test revenues.

For the three months ended Dec. 31, 2016, Genomic Health's total revenues rose to $82.7 million from $75.1 million in the same period last year. Wall street analysts had expected, on average, revenue of $84.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.